Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
J Rehabil Res Dev ; 47(6): 583-91, 2010.
Article in English | MEDLINE | ID: mdl-20848371

ABSTRACT

Access to appropriate and timely healthcare is critical to the overall health and well-being of patients with chronic diseases. In this study, we used geographic information system (GIS) tools to map Veterans Health Administration (VHA) patients with multiple sclerosis (MS) and their access to MS specialty care. We created six travel-time bands around VHA facilities with MS specialty care and calculated the number of VHA patients with MS who resided in each time band and the number of patients who lived more than 2 hours from the nearest specialty clinic in fiscal year 2007. We demonstrate the utility of using GIS tools in decision-making by providing three examples of how patients' access to care is affected when additional specialty clinics are added. The mapping technique used in this study provides a powerful and valuable tool for policy and planning personnel who are evaluating how to address underserved populations and areas within the VHA healthcare system.


Subject(s)
Ambulatory Care Facilities/organization & administration , Delivery of Health Care/organization & administration , Geographic Information Systems , Health Services Accessibility/organization & administration , Medicine/statistics & numerical data , United States Department of Veterans Affairs/organization & administration , Ambulatory Care Facilities/standards , Chronic Disease , Hospitals, Special , Hospitals, Veterans , Humans , Multiple Sclerosis/diagnosis , Multiple Sclerosis/rehabilitation , Retrospective Studies , Time Management/methods , Travel , United States , Veterans , Veterans Health
2.
Brain Res ; 1319: 131-41, 2010 Mar 10.
Article in English | MEDLINE | ID: mdl-20059990

ABSTRACT

The neuronal pathology caused by neonatal infection of rats with the PVC-211 murine leukemia virus (PVC-211 MuLV) and its underlying mechanisms are not well defined even though a loss of neurons and spongiform neurodegeneration has been reported to accompany the disease. Here we sought to identify sites of neurodegeneration using microglial reactivity as an indirect marker and to characterize microglial activation during disease progression. Using a panel of microglial antibodies including Iba1, OX-42, ED1, and anti-ferritin, we have studied the response of microglial cells to neonatal CNS infection with PVC-211 at post-infection survival times 7, 14, 21, and 28 days. We found that microglial activation occurred primarily in the spinal cord and brainstem where it gradually increased in intensity over the time course of this study. Other brain areas were relatively unremarkable in their microglial reaction to viral infection within this time frame. However, the presence of activated microglial cells was not correlated directly with the presence of viral glycoprotein (gp70), which was expressed in endothelial cells throughout the CNS. Although double-labeling of microglia with Iba1 and ED1 revealed numerous actively phagocytic microglia during disease progression, not all activated microglia were ED1-positive. In addition to the intense microglial activation, we found increased ferritin expression sporadically throughout the virus-infected brain. The ferritin-positive cells were mostly microglia that exhibited dystrophic changes and likely represented a degenerating subpopulation of microglial cells. Thus, activated microglia can co-exist with degenerating microglia in the same brain region. We attempted to localize degenerating neurons or neurites using Fluoro-Jade, anti-tau, and anti-alpha synuclein staining, but none of these procedures yielded results to indicate obvious neuronal pathology. We conclude that the visualization of microglial activation is a more sensitive measure of neuronal perturbations than direct detection of neuronal pathology which may be subtle and not produce overt degenerative changes.


Subject(s)
Central Nervous System Infections/physiopathology , Leukemia Virus, Murine , Microglia/physiology , Nerve Degeneration/physiopathology , Retroviridae Infections/physiopathology , Tumor Virus Infections/physiopathology , Animals , Animals, Newborn , Brain/physiopathology , Disease Progression , Ferritins/metabolism , Neurites/physiology , Neurons/physiology , Rats , Rats, Inbred F344 , Spinal Cord/physiopathology , Time Factors
3.
J Rehabil Res Dev ; 43(1): 111-22, 2006.
Article in English | MEDLINE | ID: mdl-16847777

ABSTRACT

Inflammatory tissue damage and the presence of reactive immunocompetent T lymphocytes, macrophages, microglia, and dendritic cells (DCs) are characteristic features in the human chronic inflammatory demyelinating disease, multiple sclerosis (MS). Together, these cells orchestrate the inflammation and immunopathogenesis underlying the MS autoimmune disease processes and all up-regulate the same voltage-gated potassium (K(v)) channel, K(v)1.3, when fully activated. Only microglia, which mediate central nervous system (CNS) inflammatory processes (possibly playing a dual role of CNS protection and mediation of neuroinflammation/ neurodegeneration), and DC, which are pivotal to the induction of T cell responses, express the distinct K(v)1.5 prior to K(v)1.3 up-regulation. Although the precise functional roles of first K(v)1.5 and then K(v)1.3 channels are unclear, their differential expression is likely a common mechanism used by both microglia and DC, revealing K(v)1.5 (in addition to K(v)1.3) as a potentially important target for the development of new immunomodulatory therapies in MS.


Subject(s)
Anti-Inflammatory Agents/therapeutic use , Central Nervous System Diseases/drug therapy , Multiple Sclerosis/drug therapy , Potassium Channel Blockers/therapeutic use , Potassium Channels, Voltage-Gated/metabolism , Central Nervous System Diseases/diagnosis , Dendritic Cells/cytology , Dendritic Cells/drug effects , Female , Humans , Male , Multiple Sclerosis/diagnosis , Nerve Degeneration/prevention & control , Potassium Channels, Voltage-Gated/drug effects , Prognosis , Risk Assessment , Severity of Illness Index , T-Lymphocytes/cytology , T-Lymphocytes/drug effects , Treatment Outcome
4.
J Virol ; 78(15): 8392-9, 2004 Aug.
Article in English | MEDLINE | ID: mdl-15254211

ABSTRACT

The murine leukemia virus (MLV) TR1.3 provides an excellent model to study the wide range of retrovirus-induced central nervous system (CNS) pathology and disease. TR1.3 rapidly induces thrombotic events in brain microvessels and causes cell-specific syncytium formation of brain capillary endothelial cells (BCEC). A single amino acid substitution, W102G, in the MLV envelope protein (Env) regulates the pathogenic effects. The role of Env in determining this disease phenotype compared to the induction of spongiform encephalomyelitis with a longer latency, as seen in several other MLV and in human retroviruses, was determined by studying in vitro-attenuated TR1.3. Virus cloned from this selection, termed TRM, induced progressive neurological disease characterized by ataxia and paralysis and the appearance of spongiform neurodegeneration throughout the brain stem and spinal cord. This disease was associated with virus replication in both BCEC and highly ramified glial cells. TRM did not induce syncytium formation, either in vivo or in vitro. Sequence and mutational analyses demonstrated that TRM contained a reversion of Env G102W but that neurological disease mapped to the single amino acid substitution Env S159P. The results demonstrate that single nucleotide changes within disparate regions of Env control dramatically different CNS disease patterns.


Subject(s)
Central Nervous System Diseases/etiology , Leukemia Virus, Murine/pathogenicity , Viral Envelope Proteins/chemistry , Animals , Cell Line , Central Nervous System Diseases/pathology , Central Nervous System Diseases/virology , Coturnix , Female , Membrane Fusion , Mice , Mice, Inbred BALB C , Tropism , Viral Envelope Proteins/physiology
5.
Virology ; 321(1): 57-64, 2004 Mar 30.
Article in English | MEDLINE | ID: mdl-15033565

ABSTRACT

Exposure of newborn BALB/c mice to murine leukemia virus (MLV) TR1.3 induces fusion of brain capillary endothelial cells (BCEC), loss of cerebral vessel integrity, hemorrhagic stroke, and death. Although TR1.3 infects endothelial cells in multiple organs, syncytia are only observed in BCEC. To determine if viral and cellular factors are responsible for selective syncytia formation, capillary endothelial cells (CEC) from multiple organs were assayed in vitro for MLV infection and cell fusion. Following incubation with virus, all CEC were infected to an equal extent as determined by expression of MLV envelope and infectious virus production; however, MLV-induced syncytia were only observed in TR1.3-infected BCEC cultures. These in vitro results mirror the in vivo pattern of TR1.3 MLV infection and neuropathology, and definitively show that selective fusion and pathology of BCEC by MLV is determined by properties unique to BCEC as contrasted to other endothelial cell types.


Subject(s)
Brain/blood supply , Endothelium, Vascular/virology , Giant Cells/virology , Leukemia Virus, Murine/pathogenicity , Animals , Cell Division , Cells, Cultured , Endothelium, Vascular/pathology , Leukemia Virus, Murine/growth & development , Mice , Mice, Inbred BALB C , Models, Animal , Organ Specificity , Retroviridae Proteins, Oncogenic/analysis , Viral Envelope Proteins/analysis
6.
J Virol ; 77(9): 5145-51, 2003 May.
Article in English | MEDLINE | ID: mdl-12692217

ABSTRACT

PVC-211 murine leukemia virus (MuLV) is a neuropathogenic variant of Friend MuLV (F-MuLV) which causes a rapidly progressive spongiform neurodegenerative disease in rodents. The primary target of PVC-211 MuLV infection in the brain is the brain capillary endothelial cell (BCEC), which is resistant to F-MuLV infection. Previous studies have shown that changes in the envelope gene of PVC-211 MuLV confer BCEC tropism to the virus. However, little is known about how infection of BCECs by PVC-211 MuLV induces neurological disease. Previous results suggest that nitric oxide (NO), which has been implicated as a potential neurotoxin, is involved in PVC-211 MuLV-induced neurodegeneration. In this study, we show that expression of inducible nitric oxide synthase (iNOS), which produces NO from L-arginine, is induced in BCECs from PVC-211 MuLV-infected rats. Furthermore, elevated levels of a 32-kDa cellular protein modified by 3-nitrotyrosine, which is a hallmark of NO production, were observed in virus-infected BCECs. BCECs from rats infected with BCEC-tropic but nonneuropathogenic PVF-e5 MuLV, which is a chimeric virus between PVC-211 MuLV and F-MuLV, fail to induce either iNOS expression or elevation of tyrosine nitration of a 32-kDa protein. These results suggest that expression of iNOS and nitration of tyrosine residues of a 32-kDa protein in PVC-211 MuLV-infected BCECs may play an important role in neurological disease induction.


Subject(s)
Brain/blood supply , Endothelium, Vascular/virology , Leukemia Virus, Murine/pathogenicity , Nitric Oxide Synthase/biosynthesis , Proteins/metabolism , Tyrosine/analogs & derivatives , Tyrosine/metabolism , 3T3 Cells , Animals , Brain/enzymology , Brain/metabolism , Brain/virology , Capillaries/virology , Cells, Cultured , Endothelium, Vascular/cytology , Endothelium, Vascular/enzymology , Endothelium, Vascular/metabolism , Mice , Nervous System/pathology , Nervous System/virology , Nitric Oxide Synthase Type II , Rats , Rats, Inbred F344 , Retroviridae Infections/physiopathology , Retroviridae Infections/virology , Tumor Virus Infections/physiopathology , Tumor Virus Infections/virology
SELECTION OF CITATIONS
SEARCH DETAIL
...